Chimerix and ContraVir Pharmaceuticals have entered into a strategic collaboration for the clinical development and commercialization of CMX157, a highly potent analog of the antiviral drug tenofovir DF (Viread). ContraVir will license CMX157 from Chimerix in exchange for an upfront payment of 120,000 shares valued at $1.2 million. Chimerix is also eligible to receive as much as $20 million in clinical, regulatory and commercial milestones, as well as royalties on sales in the in the U.S. and Eu...